Curewell Capital buys majority stake in device maker ECA Medical
What's the deal? Curewell CapitalDealroom has a profile for this one. Try Dealroom →, a Los Angeles-based private equity firm focused on healthcare, has agreed to acquire a majority stake in ECA Medical from LongueVue CapitalDealroom has a profile for this one. Try Dealroom →. ECA designs and manufactures single-use instruments and surgery-ready solutions for medical device makers. Terms were not disclosed.
What does ECA do? Founded in 1979 and based in Thousand Oaks, California, ECA is a vertically integrated supplier of single-use procedural kits and precision torque-limiting instruments for original equipment manufacturers (OEMs) in orthopedics, spine, cardiovascular, and neurological devices. It handles everything from design and validation through manufacturing, sterilization, and packaging.
By the numbers: ECA has shipped more than 55 million instruments and 500,000 procedural kits worldwide. It runs five FDA-registered, ISO 13485-certified facilities in California and Utah.
What's the endgame? Curewell's capital is meant to fund ECA's growth, including expanding its product portfolio, manufacturing facilities, and capabilities. President and chief executive officer Lane Hale and the existing management team will stay on.
What they're saying: Hale called Curewell "our ideal partner for this next chapter," pointing to strong OEM demand. Michael Dal Bello, managing partner at Curewell, said ECA "has set the standard in single-use medical instrumentation."
Why now? The deal lands in a 2026 wave of investment in medical-device manufacturing and outsourcing. KKR agreed to buy device maker IntegerDealroom has a profile for this one. Try Dealroom → for about $5.7 billion, while TecometDealroom has a profile for this one. Try Dealroom → acquired Orchid Orthopedic SolutionsDealroom has a profile for this one. Try Dealroom →.
What could go wrong? The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions. With no disclosed price, there is no basis to assess valuation.
The signal: This sponsor-to-sponsor deal reflects buyer interest in established, regulated suppliers with specialized capabilities and recurring OEM relationships — not just large branded device companies.
Read more: business.theeveningleader.com
Image credit: Photographer: Meg Lomax
